7 Hidden Multibagger Stocks to Invest In

4. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Price Return over 1-Year: 75%

Potential Upside: 61.3%

Number of Hedge Fund Holders: 30

On Dec. 1, 2025, XERS announced progress on one of its pipeline products. The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for Xeris Pharmaceuticals, a subsidiary of Xeris Biopharma Holdings. The Notice pertains to the XP-8121 formulation, a once-a-week subcutaneous injection that utilizes Xeris’ proprietary XeriSol platform.

The company has pointed out that existing oral levothyroxine shows variable absorption in the gastrointestinal tract. XP-8121 solves this problem through the injection, making it viable. The CEO of the company, John Shannon, not only highlighted the achievement of this critical milestone but also praised the company’s XeriSol platform:

“We believe XP-8121 has tremendous potential to solve an unmet medical need for hypothyroidism, and this patent represents a key milestone in strengthening our intellectual property protection around this important pipeline program. It further demonstrates the ability of our XeriSol® platform to enable the development of difficult-to-formulate drugs into subcutaneous injections.”

Xeris continues to pursue additional IP protection for levothyroxine (LT4) alongside the above developments.

Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is a fast-growing biopharmaceutical company with three commercially available medications. Recorlev treats endogenous Cushing’s syndrome, Gvoke helps treat severe hypoglycemia, while Keveyis is a therapy for primary periodic paralysis.